Mengzhao Wang

Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial

Shun Lü, Jie Wang, Yan Yu et al. · Journal of Thoracic Oncology · 2021 · 278 citations · Full text

Medicine, Oncology, Pharmacology +17

Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial

Yi‐Long Wu, Ying Cheng, Jianying Zhou et al. · The Lancet Respiratory Medicine · 2020 · 258 citations

Medicine, Oncology, Pharmacology +17

Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor–Mutated Metastatic Non–Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722

Tony Mok, Kazuhiko Nakagawa, Keunchil Park et al. · Journal of Clinical Oncology · 2024 · 153 citations · Full text

Medicine, Oncology, Pharmacology +17

Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancer

Pengfei Ma, Yujie Fu, Mei‐Chun Cai et al. · Nature Communications · 2017 · 78 citations · Full text

Medicine, Genetics, Oncology +17

Sintilimab versus docetaxel as second‐line treatment in advanced or metastatic squamous non‐small‐cell lung cancer: an open‐label, randomized controlled phase 3 trial (ORIENT‐3)

Yuankai Shi, Lin Wu, Xinmin Yu et al. · Cancer Communications · 2022 · 58 citations · Full text

Medicine, Oncology, Pharmacotherapy +10